Short answer
agilon health, inc. (AGL) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1.5B (up 5.9% year over year) with net income of $35M.
Q3 2026 key financials · XBRL
- Revenue
- $1.5B
- +5.9% YoY · +1.7% QoQ
- Net income
- $35M
- +131.7% YoY · +94.4% QoQ
- Operating margin
- 1.6%
- EPS (diluted)
- $1.96
- +92.2% QoQ
Source: XBRL data from the agilon health, inc. (AGL) Q3 2026 10-Q on SEC EDGAR. USD.
agilon health, inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $1.52B, up 6% YoY from $1.43B, driven by higher PMPM capitation rates and premium yield
- MSER 88.5% vs 104.0% YoY, with medical services expense down 10% to $1.34B
- Best performance: profitable geographies, physician incentive expense $54.9M vs $(18.2)M YoY
- Net income $34.9M vs $(110.2)M; Adjusted EBITDA $63.7M vs $(91.5)M
- Cash and restricted cash $246.4M, marketable securities $65.4M; nine-month operating cash flow $16.3M vs $(85.2)M
Risk Factors
- Newly triggered liquidity risk: Third Amendment requires minimum Total Cash of $50.0 million daily and 100% cash collateralization of letters of credit
- Most materially updated debt risk: Term-loan maturity extended to February 18, 2028, while revolving commitments fell to $90.0 million
- Regulatory and compliance risk: CMS risk-adjustment settlements typically arrive 12 to 18 months later, creating revenue reversal exposure
- Operational risk: Company bears full medical-cost risk for approximately 453,600 Medicare Advantage members
- Financial concentration risk: Substantially all receivables come from a small number of payors
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other agilon health, inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.